Cadonilimab (AK104)

About Akeso

Founded in 2012, Akeso has established itself as a cornerstone of China's biopharmaceutical innovation, with a mission to develop world-class, first-in-class and best-in-class therapies. Its achievements include the global firsts of PD-1/CTLA-4 (cadonilimab) and PD-1/VEGF (ivonescimab) bispecific antibodies, a landmark $5B+ out-licensing deal, and FDA approval for its PD-1 inhibitor. The company's strategy leverages its integrated ACE Platform for end-to-end drug development, aggressive global partnerships, and a diversified pipeline spanning oncology, autoimmunity, and metabolic diseases to drive sustainable growth.

About Akeso

Founded in 2012, Akeso has established itself as a cornerstone of China's biopharmaceutical innovation, with a mission to develop world-class, first-in-class and best-in-class therapies. Its achievements include the global firsts of PD-1/CTLA-4 (cadonilimab) and PD-1/VEGF (ivonescimab) bispecific antibodies, a landmark $5B+ out-licensing deal, and FDA approval for its PD-1 inhibitor. The company's strategy leverages its integrated ACE Platform for end-to-end drug development, aggressive global partnerships, and a diversified pipeline spanning oncology, autoimmunity, and metabolic diseases to drive sustainable growth.

About Akeso

Founded in 2012, Akeso has established itself as a cornerstone of China's biopharmaceutical innovation, with a mission to develop world-class, first-in-class and best-in-class therapies. Its achievements include the global firsts of PD-1/CTLA-4 (cadonilimab) and PD-1/VEGF (ivonescimab) bispecific antibodies, a landmark $5B+ out-licensing deal, and FDA approval for its PD-1 inhibitor. The company's strategy leverages its integrated ACE Platform for end-to-end drug development, aggressive global partnerships, and a diversified pipeline spanning oncology, autoimmunity, and metabolic diseases to drive sustainable growth.

Therapeutic Areas

Other Recurrent/Metastatic Cervical Cancer Drugs